This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.
This week, we will discuss the fresh-off-the-press KDIGO guidelines on Diabetes. RAS Blockade and SGLT2i, needless to say - but is there more? There is. Read on as we break it down for you.
SGLT2 inhibitors lower MACE in Diabetes. Then they decrease kidney failure in DM. Then Heart Failure in DM and non-DM. And now decrease kidney failure in nonDM too! Let’s see how strong the data really is
How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.